Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 8/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13638135 | 0.83 | SMN1; SMN2 (0.56) | EPHX1SMN1; SMN2ALDH1A1MAPTHPGD | |
| SCHEMBL13638134 | 0.75 | ALDH1A1 (0.39) | EPHX1EPHX2SMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL31532555 | 0.73 | NPSR1 (0.53) | EPHX1SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL10085163 | 0.73 | NPSR1 (0.53) | EPHX1SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL21340181 | 0.73 | NPSR1 (0.53) | EPHX1SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL10078381 | 0.73 | NPSR1 (0.53) | EPHX1SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL14110289 | 0.73 | NPSR1 (0.53) | EPHX1SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL18613033 | 0.73 | NPSR1 (0.53) | EPHX1SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL13292222 | 0.71 | CYP2C19 (0.40) | — | |
| SCHEMBL9804119 | 0.71 | SMN1; SMN2 (0.52) | EPHX1EPHX2SMN1; SMN2ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281066-A1 | Treatment of proliferative disorders with amino-substituted (E)-2,6- dialkoxystyryl 4-substituted benzylsulfones | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281066-A1 | Treatment of proliferative disorders with amino-substituted (E)-2,6- dialkoxystyryl 4-substituted benzylsulfones | CCNY, CCND2, ETV6 | EPHX1 1180/4885EPHX2 1164/4885SMN1; SMN2 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.